Neuroregulation by vasoactive intestinal peptide (VIP) of mucus secretion in ferret trachea: activation of BKCachannels and inhibition of neurotransmitter release
- 29 January 1999
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 126 (1) , 147-158
- https://doi.org/10.1038/sj.bjp.0702288
Abstract
1. The aims of this study were to determine: (1) whether vasoactive intestinal peptide (VIP) regulates cholinergic and 'sensory-efferent' (tachykininergic) 35SO4 labelled mucus output in ferret trachea in vitro, using a VIP antibody, (2) the class of potassium (K+) channel involved in VIP-regulation of cholinergic neural secretion using glibenclamide (an ATP-sensitive K+ (K(ATP)) channel inhibitor), iberiotoxin (a large conductance calcium activated K+ (BK(ca)) channel blocker), and apamin (a small conductance K(ca) (SK(ca)) channel blocker), and (3) the effect of VIP on cholinergic neurotransmission using [3H]-choline overflow as a marker for acetylcholine (ACh) release. 2. Exogenous VIP (1 and 10 microM) alone increased 35SO4 output by up to 53% above baseline, but suppressed (by up to 80% at 1 microM) cholinergic and tachykininergic neural secretion without altering secretion induced by ACh or substance P (1 microM each). Endogenous VIP accounted for the minor increase in non-adrenergic, non-cholinergic (NANC), non-tachykininergic neural secretion, which was compatible with the secretory response of exogenous VIP. 3. Iberiotoxin (3 microM), but not apamin (1 microM) or glibenclamide (0.1 microM), reversed the inhibition by VIP (10 nM) of cholinergic neural secretion. 4. Both endogenous VIP (by use of the VIP antibody; 1:500 dilution) and exogenous VIP (0.1 microM), the latter by 34%, inhibited ACh release from cholinergic nerve terminals and this suppression was completely reversed by iberiotoxin (0.1 microM). 5. We conclude that, in ferret trachea in vitro, endogenous VIP has dual activity whereby its small direct stimulatory action on mucus secretion is secondary to its marked regulation of cholinergic and tachykininergic neurogenic mucus secretion. Regulation is via inhibition of neurotransmitter release, consequent upon opening of BK(Ca) channels. In the context of neurogenic mucus secretion, we propose that VIP joins NO as a neurotransmitter of i-NANC nerves in ferret trachea.Keywords
This publication has 67 references indexed in Scilit:
- Pre- and Post-Junctional Effects of VIP-Like Peptides in Guinea Pig Tracheal Smooth MuscleRespiration, 1997
- Neuroeffector mechanisms: The interface between inflammation and neuronal responsesJournal of Allergy and Clinical Immunology, 1996
- Neuroregulation of the nose and bronchiClinical and Experimental Allergy, 1996
- Catalytic Autoantibodies to Vasoactive Intestinal PeptideChest, 1995
- Vagal release of vasoactive intestinal peptide can promote vagotonic tachycardia in the isolated innervated rat heartCardiovascular Research, 1994
- Modulation of cholinergic neural bronchoconstriction by endogenous nitric oxide and vasoactive intestinal peptide in human airways in vitro.Journal of Clinical Investigation, 1993
- Vasoactive intestinal peptide and neuropeptide Y coexist in non-noradrenergic sympathetic neurons to guinea pig tracheaJournal of the Autonomic Nervous System, 1992
- The effects of vasoactive intestinal polypeptide on cholinergic neurotransmission in an isolated innervated guinea pig tracheal preparationRespiration Physiology, 1990
- Absence of Immunoreactive Vasoactive Intestinal Polypeptide in Tissue from the Lungs of Patients with AsthmaNew England Journal of Medicine, 1989
- Apamin blocks certain neurotransmitter-induced increases in potassium permeabilityNature, 1979